These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 25047909)

  • 1. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).
    Łukaszewicz-Zając M; Mroczko B; Słowik A
    J Neural Transm (Vienna); 2014 Nov; 121(11):1387-97. PubMed ID: 25047909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases deregulation in amyotrophic lateral sclerosis.
    Sánchez-Torres JL; Yescas-Gómez P; Torres-Romero J; Espinosa OR; Canovas LL; Tecalco-Cruz ÁC; Ponce-Regalado MD; Alvarez-Sánchez ME
    J Neurol Sci; 2020 Dec; 419():117175. PubMed ID: 33068904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Matrix Metalloproteinases in Degenerative Kidney Disorders.
    Narula S; Tandon C; Tandon S
    Curr Med Chem; 2018; 25(15):1805-1816. PubMed ID: 29210632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of metalloprotease in pathogenesis of nervous system diseases].
    Mirowska D; Członkowska A
    Neurol Neurochir Pol; 2001; 35(1):101-10. PubMed ID: 11464705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of matrix metalloproteinases in serum of patients with amyotrophic lateral sclerosis with pattern recognition methods.
    Sokolowska B; Jozwik A; Niebroj-Dobosz I; Janik P; Kwiecinski H
    J Physiol Pharmacol; 2009 Nov; 60 Suppl 5():117-20. PubMed ID: 20134051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of matrix metalloproteinases in the pathogenesis of multiple sclerosis].
    Kurzepa J; Bartosik-Psujek H; Suchozebrska-Jesionek D; Rejdak K; Stryjecka-Zimmer M; Stelmasiak Z
    Neurol Neurochir Pol; 2005; 39(1):63-7. PubMed ID: 15735992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS).
    Lukaszewicz-Zając M; Mroczko B; Kornhuber J; Lewczuk P
    J Neural Transm (Vienna); 2014 May; 121(5):469-77. PubMed ID: 24366530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases.
    Gueders MM; Foidart JM; Noel A; Cataldo DD
    Eur J Pharmacol; 2006 Mar; 533(1-3):133-44. PubMed ID: 16487964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study.
    Mroczko B; Groblewska M; Barcikowska M
    J Alzheimers Dis; 2013; 37(2):273-83. PubMed ID: 23792694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix Metalloproteinases in Kidney Disease: Role in Pathogenesis and Potential as a Therapeutic Target.
    Parrish AR
    Prog Mol Biol Transl Sci; 2017; 148():31-65. PubMed ID: 28662825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Matrix metalloproteinases and their tissue inhibitors].
    Trojanek J
    Postepy Biochem; 2012; 58(3):353-62. PubMed ID: 23373420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metalloproteinase alterations in the bone marrow of ALS patients.
    Bossolasco P; Cova L; Calzarossa C; Servida F; Mencacci NE; Onida F; Polli E; Lambertenghi Deliliers G; Silani V
    J Mol Med (Berl); 2010 Jun; 88(6):553-64. PubMed ID: 20091292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer.
    Herszényi L; Hritz I; Lakatos G; Varga MZ; Tulassay Z
    Int J Mol Sci; 2012 Oct; 13(10):13240-63. PubMed ID: 23202950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications.
    Karthikeyan VJ; Lane DA; Beevers DG; Lip GY; Blann AD
    J Hum Hypertens; 2013 Feb; 27(2):72-8. PubMed ID: 22418748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TIMPs tango with MMPs and more in the central nervous system.
    Crocker SJ; Pagenstecher A; Campbell IL
    J Neurosci Res; 2004 Jan; 75(1):1-11. PubMed ID: 14689443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease.
    Zakiyanov O; Kalousová M; Zima T; Tesař V
    Adv Clin Chem; 2021; 105():141-212. PubMed ID: 34809827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.
    Maskos K; Bode W
    Mol Biotechnol; 2003 Nov; 25(3):241-66. PubMed ID: 14668538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer.
    Groblewska M; Siewko M; Mroczko B; Szmitkowski M
    Folia Histochem Cytobiol; 2012 Apr; 50(1):12-9. PubMed ID: 22532131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.
    Bourboulia D; Stetler-Stevenson WG
    Semin Cancer Biol; 2010 Jun; 20(3):161-8. PubMed ID: 20470890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.